This ELISA kit provides quantitative measurement of soluble VEGFR-2/Flk-1 (sVEGFR-2) in human samples, supporting research into angiogenesis-driven cardiovascular pathology. Because circulating sVEGFR-2 levels shift in response to endothelial activation and anti-angiogenic therapy, researchers need an assay calibrated to capture both baseline and disease-modulated concentrations across translational sample types.
Detection Range: The 0.078–5 ng/mL range aligns with reported circulating sVEGFR-2 concentrations in human plasma, which typically fall between 5–12 ng/mL in healthy adults and can decrease significantly during anti-VEGF treatment or heart failure progression. Most serum and plasma samples will require a modest 2–5× dilution, while tissue homogenates from ischemic or tumor-adjacent myocardium can generally be assayed with minimal adjustment.
Sensitivity: At 0.039 ng/mL, the assay detects sVEGFR-2 in low-abundance contexts such as diluted plasma from patients on VEGF pathway inhibitors or conditioned media from endothelial cell cultures with suppressed receptor shedding.
Sample Compatibility: Validation across serum, plasma, and tissue homogenates enables paired analyses linking circulating sVEGFR-2 to local receptor expression in ischemic or infarcted myocardial tissue within the same study.
Assay Efficiency: The 1–5 hour protocol and 50–100 µL sample volume accommodate serial blood draws from longitudinal cardiovascular monitoring studies where repeated sampling limits available volume.
This kit is well-suited for studies of myocardial ischemia, anti-angiogenic cardiotoxicity, and peripheral artery disease biomarker discovery.